Replay
Biotechnology company developing a novel toolkit to deliver large DNA payloads efficiently to any cell type, addressing the growing cell and gene therapy market with high-capacity delivery systems.
Notes
Replay (formerly Replay Bio) is a biotechnology company creating innovative tools to deliver large DNA payloads efficiently to any cell type. The company addresses a critical challenge in the cell and gene therapy market: the ability to deliver large genetic constructs that exceed the capacity of traditional viral vectors like AAV.
Their platform includes high-capacity delivery systems that can accommodate much larger genetic payloads than conventional gene therapy approaches, opening up new therapeutic possibilities for diseases that require delivery of large genes or multiple genes.
Team
- Adrian Woolfson, M.D., Ph.D. - Co-founder & Chief Executive Officer
- LinkedIn: linkedin.com/in/adrianwoolfson
- Pablo Cironi, Ph.D. - Co-founder & Chief Scientific Officer
- LinkedIn: linkedin.com/in/pablocironi
Additional Research Findings
- High-capacity DNA delivery platform
- Addresses limitations of AAV and other viral vectors
- Focus on large DNA payload delivery
- Targeting cell and gene therapy applications
- San Diego-based operations
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| OMX Ventures | San Francisco, California, USA | biotech-focused | seedseries-a | 23 |